Medical device manufacturing quotations cannot be compared reliably by unit price alone. One proposal may cover only materials and assembly labor, while another includes incoming inspection, controlled documentation, manufacturing oversight, and packaging operations [1]. The higher-priced quotation may therefore describe a more complete production scope, not a less competitive supplier. A defensible comparison begins by defining the device configuration, design maturity, expected volumes, quality requirements, validation activities, packaging specifications, and production timeline, then asks each manufacturer to quote against those identical assumptions [1]. This article explains the workflow, the technical decision points that change quotation meaning, the evidence limitations that persist even after normalization, and a concrete evaluation example for a hypothetical catheter component program.

Why Unit Price Produces Misleading Comparisons

Comparing contract manufacturers on quoted unit price leads to misleading conclusions when proposals do not include equivalent services. Pathway Medtech notes that one manufacturer may price primarily materials and assembly labor, while another includes incoming inspection, controlled documentation, manufacturing oversight, and packaging operations [1]. The second proposal may appear more expensive while representing a more complete picture of the work required to establish and maintain production. A meaningful comparison therefore considers the total scope of each proposal, including activities that remain the responsibility of the medical device company [1].

The same distortion appears in component sourcing. Fictiv states that successful sourcing depends on more than price and lead time; it requires suppliers capable of consistently producing compliant parts while supporting documentation, validated processes, and engineering collaboration throughout the product lifecycle [2]. A supplier certified for precision machining is not automatically qualified for regulated medical manufacturing, so the practical question is whether the certification scope matches the component and process [2]. Quotation comparison must therefore treat certification scope and documentary obligations as part of the quoted deliverable, not as optional add-ons.

Normalizing Scope Before Comparing Numbers

A useful manufacturing quotation begins with a clear understanding of the device and its current development stage. Manufacturers generally need information about device configuration, material requirements, expected production volume, assembly complexity, quality expectations, and known validation or packaging requirements [1]. Engineering drawings, CAD files, bills of materials, development status, and assembly requirements should be available before quoting; if substantial information remains unresolved, an engineering assessment may be necessary before an accurate production quotation can be established [1].

Kinmed recommends structuring the RFQ to reduce ambiguity and let vendors answer comprehensively. The document should include a company and project overview, mandatory product certifications such as CE or FDA 510(k), quality management system certifications such as ISO 13485 or ISO 9001, documentation required with shipment, target country registration requirements, quantities, delivery timelines, Incoterms, payment conditions, and warranty expectations [3]. Suppliers price differently when they see long-term growth, so stating whether a pilot order may scale to larger volumes changes the commercial basis of the quotation [3].

A Weighted Comparison Framework

Kinmed proposes a scoring framework with five weighted criteria: technical compliance at 25%, regulatory documentation at 20%, total cost of ownership at 25%, delivery and logistics at 15%, and supplier reliability at 15% [3]. Total cost of ownership includes unit price plus shipping, duties, installation, training, and maintenance costs [3]. Before scoring, the buyer should ask each supplier about production capacity, lead time, quality control process, defect rate, inspection method, regulatory history, recalls, reference clients, raw material sourcing, safety stock, and business continuity planning [3].

This framework is a suggestion, not a validated standard. It does not replace verification of production capability, which Kinmed states is the only way to confirm that supplier claims match actual operations [3]. The weights should be adjusted to the device classification, volume, and risk profile of the specific program.

Nonrecurring Costs That Change the Comparison

Engineering, tooling, fixtures, equipment qualification, process validation, packaging validation, and sterilization development may be quoted separately from recurring production costs. Pathway Medtech advises medical device companies to request a clear explanation of included services, exclusions, assumptions, and potential nonrecurring expenses before comparing proposals [1]. Two quotations with identical unit prices can diverge sharply once tooling ownership, validation scope, and engineering responsibility are assigned to one party or the other.

BMP Medical identifies tooling as often the largest single capital commitment in plastic injection-molded device programs, alongside material selection, validation scope, production volume, and scrap or rework rates as interrelated cost drivers [6]. A resin choice affects biocompatibility, cycle time, scrap rate, regulatory classification, and unit costs, so material decisions cannot be separated from quotation economics [6]. A comparison that ignores these nonrecurring and material-driven costs will rank suppliers on an incomplete financial picture.

Documentation and Regulatory Evidence as Quotation Elements

Medical device sourcing emphasizes documentary evidence. Fictiv states that manufacturers expect shipments to include certificates of conformance, material certifications, first article inspection reports, dimensional inspection records, process certificates, and lot traceability [2]. If regulated documentation requirements are not met during quoting or purchasing, delays and additional cost follow; the simplest rule is to specify documentation on the purchase order, not later [2]. Material substitutions require documented approvals because the material is critical to the product definition [2].

The FDA's Quality Management System Regulation became effective February 2, 2026, amending 21 CFR part 820 and incorporating ISO 13485:2016 by reference [7]. Device classification determines regulatory requirements: most Class I devices are exempt from 510(k), most Class II devices require 510(k), and most Class III devices require premarket approval [7]. A quotation comparison should verify that each supplier's stated quality system and documentation scope align with the device classification and target market, rather than assuming a generic certification covers the specific component or process [2].

A Concrete Evaluation Example for a Catheter Component

Consider a hypothetical program for a thin-walled PTFE liner used in a coronary catheter. The buyer requests quotations from two suppliers. Supplier A quotes a lower unit price for extrusion only. Supplier B quotes a higher unit price that includes raw material reformulation, controlled nitrogen-based expansion, automated cut-to-length from 0.5 to 120 inches, and final optical and dimensional metrology [5]. Cordis, as a named contract manufacturing development organization, describes these post-extrusion and inspection steps as part of its component production platform [5].

The comparison should not simply select the lower unit price. The buyer must determine whether Supplier A's quotation excludes expansion, cutting, and final inspection that Supplier B includes, and whether those activities would otherwise fall to the medical device company [1]. The buyer should also request process certificates for any special processes and confirm whether the supplier's certification scope covers the specific extrusion operation [2]. This example illustrates how scope normalization, not price ranking, drives the decision.